Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

Glycobiology. 2005 Jul;15(7):16R-28R. doi: 10.1093/glycob/cwi053. Epub 2005 Mar 10.

Abstract

The products of nonenzymatic glycation and oxidation of proteins and lipids, the advanced glycation end products (AGEs), accumulate in a wide variety of environments. AGEs may be generated rapidly or over long times stimulated by a range of distinct triggering mechanisms, thereby accounting for their roles in multiple settings and disease states. A critical property of AGEs is their ability to activate receptor for advanced glycation end products (RAGE), a signal transduction receptor of the immunoglobulin superfamily. It is our hypothesis that due to such interaction, AGEs impart a potent impact in tissues, stimulating processes linked to inflammation and its consequences. We hypothesize that AGEs cause perturbation in a diverse group of diseases, such as diabetes, inflammation, neurodegeneration, and aging. Thus, we propose that targeting this pathway may represent a logical step in the prevention/treatment of the sequelae of these disorders.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Aging / physiology*
  • Animals
  • Diabetes Complications / physiopathology*
  • Glycation End Products, Advanced / physiology*
  • Humans
  • Inflammation / physiopathology*
  • Mice
  • Neurodegenerative Diseases / physiopathology*
  • Oxidative Stress
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / physiology*

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic